You can see the pharma business model here: by targeting a specific strain of the spike protein and nothing else in the virus, it only needs a single mutation in the spike to survive, requiring a new mRNA vaccine for the new strain. They’re playing a very profitable game of whack-a-mole. By contrast, natural immunity learns many different viral signatures and and can attack them all at once. Variants would be a non-issue. But apparently we’re not supposed to know that.